Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 12/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 12/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 12/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | CCR5 | P51681 | 3/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572985 | 0.84 | CHRM2 (0.42) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL607715 | 0.82 | CHRM2 (0.43) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL25389501 | 0.80 | CCR5 (0.44) | EPHX2CCR5 | |
| SCHEMBL601738 | 0.77 | CHRM1 (0.38) | CHRM1EPHX2MEN1KMT2A | |
| SCHEMBL601739 | 0.77 | CHRM1 (0.38) | CHRM1EPHX2MEN1KMT2A | |
| SCHEMBL3016744 | 0.77 | CHRM1 (0.38) | CHRM1EPHX2MEN1KMT2A | |
| SCHEMBL601962 | 0.76 | CHRM4 (0.48) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL600591 | 0.76 | CHRM4 (0.48) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL600590 | 0.76 | CHRM4 (0.48) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL605131 | 0.76 | CHRM4 (0.42) | CHRM4CHRM5CHRM1CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004182-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2013-05-08 | — | — | EP | disclosed |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | CHRM4 3/4885CHRM5 4/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.